Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound?
A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) advances while market declines: Some information for investors
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...
Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results